文献速递神经肿瘤

通过检测胶质瘤患者非诊断性活检中的IDH1和TERT启动子突变避免再次活检

Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients.
PubMed 文献 · Neurosurgery · 2020-01-01

该回顾性研究对28例胶质瘤患者的非诊断性活检组织用SNaPshot聚合酶链反应检测IDH1和pTERT突变状态。17/28(61%)的非诊断性活检中检出IDH1和/或pTERT突变,pTERT突变在21例pTERT突变型胶质瘤的非诊断性活检中检出16例(76%)。作者认为分子检测可能有助于解读疑似胶质瘤患者的非诊断性活检。

要点

  • 非诊断性活检中IDH1和/或pTERT突变检出率为17/28(61%)。
  • 21例pTERT突变型胶质瘤中16例(76%)非诊断性活检可检出pTERT突变。
  • 2例IDH突变型胶质瘤的非诊断性活检均检出IDH1突变。

核心结论

  • 在本系列中,胶质瘤患者非诊断性活检的较高比例可检出IDH1和pTERT突变,分子检测可能有助于解读疑似胶质瘤患者的非诊断性活检。

研究设计与样本

  • 回顾性研究,采用SNaPshot聚合酶链反应评估28例胶质瘤患者非诊断性活检的IDH1和pTERT突变状态。
  • 非诊断性活检方式包括针刺活检25例、开放或内镜活检3例。
  • 非诊断性活检组织表现为轻度胶质细胞增生、出血和/或坏死。

主要发现

  • 再次活检23例或后续手术切除5例后诊断为:IDH1野生型pTERT突变型胶质瘤(胶质母细胞瘤16例、星形细胞瘤4例)、IDH1突变型pTERT突变型少突胶质细胞瘤1例、IDH1突变型pTERT野生型星形细胞瘤1例、IDH1野生型pTERT野生型胶质母细胞瘤6例。
  • 2例IDH突变型胶质瘤的非诊断性活检中均检出IDH1突变。
  • 21例pTERT突变型胶质瘤中16例(76%)的非诊断性活检检出pTERT突变。
  • 28例非诊断性活检中17例(61%)检出IDH1和/或pTERT突变。

关键数值与推荐

  • 基于上述结果和影像特征回顾分析非诊断性活检,提示6例患者可高置信度诊断为「分子胶质母细胞瘤」而避免再次活检。

临床怎么用

  • 作者认为分子检测可能有助于解读疑似胶质瘤患者的非诊断性活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biopsies in patients with a suspected glioma are occasionally nondiagnostic. OBJECTIVE: To explore the utility of molecular testing in this setting by determining whether IDH1 and TERT promoter (pTERT) mutations could be detected in nondiagnostic biopsies from glioma patients. METHODS: Using SNaPshot polymerase chain reaction, we retrospectively assessed IDH1 and pTERT mutation status in nondiagnostic biopsies from 28 glioma patients. RESULTS: The nondiagnostic biopsy (needle biopsy n = 25, open or endoscopic biopsy n = 3) consisted of slight glial cell hypercellularity, hemorrhage, and/or necrosis. After another biopsy (n = 23) or a subsequent surgical resection (n = 5) the diagnosis was an IDH1-wildtype (WT) pTERT-mutant glioma (glioblastoma n = 16, astrocytoma n = 4), an IDH1-mutant pTERT-mutant oligodendroglioma (n = 1), an IDH1-mutant pTERT-WT astrocytoma (n = 1), and an IDH1-WT pTERT-WT glioblastoma (n = 6). An IDH1 mutation was identified in the nondiagnostic biopsies of the 2 IDH-mutant gliomas, and a pTERT mutation in the nondiagnostic biopsies of 16 out of the 21 of pTERT mutant-gliomas (76%). Overall, an IDH1 and/or a pTERT mutation were detected in 17 out of 28 (61%) of nondiagnostic biopsies. Retrospective analysis of the nondiagnostic biopsies based on these results and on imaging characteristics suggested that a new biopsy could have been avoided in 6 patients in whom a diagnosis of "molecular glioblastoma" could have been done with a high level of confidence. CONCLUSION: In the present series, IDH1 and pTERT mutations could be detected in a high proportion of nondiagnostic biopsies from glioma patients. Molecular testing may facilitate the interpretation of nondiagnostic biopsies in patients with a suspected glioma.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Barritault M, Picart T, Poncet D, et al. Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients. Neurosurgery. 2020. PMID: 32107549. doi:10.1093/neuros/nyaa025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。